Ivy Beeren

Ms. Ivy Beeren

Department for Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in European Urology Oncology
Verified
Journal Article
Open access
IBIvy Beeren
Ivy Beeren
NKNena E. Klerks
Nena E. Klerks
KAKatja K. Aben
Katja K. Aben
JOJorg R. Oddens
Jorg R. Oddens
JWJ. Alfred Witjes
J. Alfred Witjes
Alina VrielingAlina Vrieling
Alina Vrieling
The health-related quality of life (HRQoL) of patients with non-muscle-invasive bladder cancer (NMIBC) may be impaired due to the chronic and burdensome disease course, but longitudinal data are limited. To evaluate HRQoL outcomes during the first 4 yr after NMIBC diagnosis, and to compare HRQoL across patient characteristics and with a normative population. Patients with NMIBC (n = 1019) were included from the multicentre prospective cohort UroLife. Data were collected at 6 wk (baseline), and 3, 15, and 51 mo after diagnosis. Longitudinal reference data were obtained from an age- and sex-matched normative population (n = 490). Cancer- and NMIBC-specific HRQoL outcomes (range 0-100) were evaluated by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EORTC QLQ-NMIBC24 questionnaires, respectively. Linear mixed modelling was used to analyse within-group changes and between-group differences. The majority of HRQoL outcomes remained stable over time. Observed changes were only of small clinical relevance. Improvements were noted in insomnia, social functioning, and three NMIBC-specific symptoms, while minor deteriorations in appetite and diarrhoea lasted until 51 mo. HRQoL in some domains was worse for high-grade NMIBC, high European Association of Urology (EAU) risk group, initial Bacillus Calmette-Guérin (BCG) treatment, being female, and being younger (<65 yr); yet differences were few, small, and temporary. No differences were observed across recurrence status. Compared with a normative population, clinically relevant worse scores were observed for six of 15 outcomes, which mostly recovered at 51 mo, except for minor symptoms of appetite loss and diarrhoea. No remarkable changes in HRQoL were observed during the first 4 yr after NMIBC diagnosis. Grade, EAU risk group, initial treatment, recurrence, sex, and age did not importantly affect HRQoL. HRQoL was largely comparable with that of the general population, especially after 4 yr. Quality of life is not largely affected during the first 4 yr after non-muscle-invasive bladder cancer diagnosis.

15 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
IBIvy Beeren
Ivy Beeren
LGLiesbeth de Goeij
Liesbeth de Goeij
RDRana Dandis
Rana Dandis
NVNikoletta Vidra
Nikoletta Vidra
MZMoniek van Zutphen
Moniek van Zutphen
Alina VrielingAlina Vrieling
Alina Vrieling
The aim of our study was to investigate adherence to lifestyle recommendations and lifestyle changes after diagnosis in patients with non-muscle invasive bladder cancer (NMIBC). Second, we aimed to identify distinct trajectories of lifestyle change and their correlates. We analysed data of 935 patients with NMIBC from a prospective cohort study at six weeks (evaluating pre-diagnostic lifestyle), three months, and fifteen months after diagnosis. An overall lifestyle score (range 0–7) was calculated based on the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations focusing on diet, body mass index, and physical activity. Linear mixed models were used to analyse absolute lifestyle changes over time. Distinct trajectories of change were identified with latent class trajectory models. We found an overall lifestyle score of 3.3 which remained constant over time. The largest lifestyle changes were observed for the consumption of red and processed meat (−96 g/week) and fruit and vegetables (−38 g/day). Two to four trajectory groups were identified for each single lifestyle behaviour. Correlates differed per trajectory group. In conclusion, adherence to the WCRF/AICR recommendations was low. Small to moderate changes in and different trajectories of single lifestyle behaviours were observed. Effective strategies for lifestyle improvement are warranted.

13 January 2023 in International Journal of Cancer
Verified
Journal Article
Open access
NVNikoletta Vidra
Nikoletta Vidra
IBIvy Beeren
Ivy Beeren
MZMoniek van Zutphen
Moniek van Zutphen
KAKatja K. Aben
Katja K. Aben
EKEllen Kampman
Ellen Kampman
Alina VrielingAlina Vrieling
Alina Vrieling
Although the role of lifestyle in health‐related quality of life (HRQoL) outcomes has been increasingly recognized for various types of cancer, evidence in patients with non‐muscle invasive bladder cancer (NMIBC) is very limited. We aimed to evaluate the longitudinal association between adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) lifestyle recommendations and HRQoL in patients with NMIBC. This study included 1029 patients with NMIBC recruited between May 2014 and April 2017 from the Dutch multi‐centre prospective cohort study UroLife. Lifestyle and HRQoL data were collected at 6 weeks (baseline), 3 months and 15 months after diagnosis. Information on body mass index (BMI), physical activity, diet and alcohol was used to compute the standardized WCRF/AICR adherence score (0‐7). HRQoL outcomes were evaluated by the EORTC QLQ‐C30. Linear mixed models were used to assess longitudinal confounder‐adjusted associations between the WCRF/AICR adherence score and HRQoL outcomes. Adherence to each additional WCRF/AICR recommendation was associated with better global quality of life, physical, role and social functioning, and less fatigue. We found stronger inter‐individual than intra‐individual associations, suggesting that associations were mainly driven by between‐subject differences. Higher adherence to the BMI, physical activity and dietary recommendations was associated with better scores for most HRQoL outcomes, while adherence to the alcohol recommendation (ie, non‐consumption) was associated with worse HRQoL. Following the WCRF/AICR lifestyle recommendations may improve HRQoL in patients with NMIBC. Intervention studies are needed to establish whether the association between lifestyle and HRQoL is causal.

16 April 2025 in BJU International
Verified
Journal Article
Open access
SNSiberyn T. Nuijens
Siberyn T. Nuijens
LHLisa M.C. van Hoogstraten
Lisa M.C. van Hoogstraten
NTNoëlle B. Terpstra
Noëlle B. Terpstra
IBIvy Beeren
Ivy Beeren
Alina VrielingAlina Vrieling
Alina Vrieling
KAKatja K.H. Aben
Katja K.H. Aben
Objectives: To evaluate the impact of treatment for localised muscle‐invasive bladder cancer (MIBC) during the first 2 years after diagnosis. Patients and Methods: A prospective cohort study was conducted including patients diagnosed with non‐metastatic (cM0) MIBC between November 2017 and November 2019 in the Netherlands. Health‐related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30) as well as the MIBC‐specific QLQ‐BLM30 module. Questionnaires were administered at baseline (pre‐treatment) and at 6, 12 and 24 months after diagnosis. Patients were grouped by treatment: neoadjuvant chemotherapy (NAC) and radical cystectomy (RC), upfront RC, chemoradiation, and radiotherapy. Linear mixed models were used to assess HRQoL changes over time per treatment group. Results: A total of 518 patients participated in quality of life measurements (46% response rate). After excluding 14 patients who did not complete the EORTC QLQ‐C30 and 114 for baseline completion after start of treatment, a total of 390 patients were included of whom 105 underwent NAC and RC, 148 underwent upfront RC, 58 underwent chemoradiation, and 79 underwent radiotherapy alone. Over time, clinically relevant improvements in emotional functioning and future perspective were observed across all treatment groups. However, a temporary worsening in physical functioning was observed at 6 months. Patients treated with RC (with or without NAC) experienced persistent deteriorations in body image and sexual functioning up to at least 2 years after diagnosis, although urostomy‐related outcomes improved. Patients undergoing chemoradiation showed improvements in urinary symptoms, while those receiving radiotherapy reported significant worsening of dyspnoea over time. Conclusion: In this largest population‐based study to date on HRQoL in MIBC, HRQoL largely recovered to baseline levels during the first 2 years after diagnosis. However, persistent deteriorations in physical and cognitive functioning, body image, and sexual function were observed, particularly in patients treated with RC (with or without NAC).

30 June 2025 in International Journal of Cancer
Verified
Journal Article
Open access
IBIvy Beeren
Ivy Beeren
JKJoann Kiebach
Joann Kiebach
JHJasper P. Hof
Jasper P. Hof
LBLaurien M. Buffart
Laurien M. Buffart
KAKatja K. H. Aben
Katja K. H. Aben
Alina VrielingAlina Vrieling
Alina Vrieling
Previous studies in solid tumors link high physical activity (PA) levels to lower cancer recurrence risk, but evidence is lacking for patients with non‐muscle invasive bladder cancer (NMIBC). We evaluated the association between (changes in) PA (total, moderate‐to‐vigorous PA, leisure‐time PA, and Dutch PA guideline adherence) and risks of NMIBC recurrence and progression. Patients diagnosed between 2014 and 2021 were recruited for the multi‐center prospective cohort UroLife. Participants reported prediagnosis PA at 6 weeks ( n = 1414) and postdiagnosis PA at 3 and 15 months after diagnosis ( n = 1275). Multivariable proportional hazards models were used to assess the association of PA levels with risk of first and multiple recurrence(s) and progression. During a median total follow‐up time of 4.6 years, 501 patients had ≥1 recurrence, 144 had ≥2 recurrences, and 157 had progression. Higher pre‐ and postdiagnosis PA levels were not significantly associated with risks of first recurrence, multiple recurrences, and progression. Pre‐to‐postdiagnosis increases of 10 metabolic equivalent of task hour/week in leisure‐time PA, equivalent to 3–4 h/week of walking or 1 h/week of running, were significantly associated with lower progression risk (hazard ratio at 3 months: 0.94, 95% confidence interval: 0.89–0.99). The self‐reported and relatively high PA levels could have limited the detection of associations. In conclusion, higher PA levels before or after NMIBC diagnosis were not significantly associated with lower recurrence or progression risk. Although pre‐to‐postdiagnosis increases in leisure‐time PA were associated with lower progression risk, further research is necessary before specific PA recommendations can be formulated for patients with NMIBC.

25 January 2025 in BJU International
Verified
Journal Article
Open access
IBIvy Beeren
Ivy Beeren
HMHilde Meijer
Hilde Meijer
AHAntoine G. van der Heijden
Antoine G. van der Heijden
KAKatja K.H. Aben
Katja K.H. Aben
JWJ. Alfred Witjes
J. Alfred Witjes
Alina VrielingAlina Vrieling
Alina Vrieling
Objectives: To evaluate the association of pre‐ and post‐diagnosis fluid intake with non‐muscle‐invasive bladder cancer (NMIBC) recurrence and progression risk. Patients and Methods: Data were used from the multicentre prospective cohort study UroLife. Participants reported pre‐diagnosis fluid intake at 6 weeks (food frequency questionnaire [FFQ]) ( n = 1322) and post‐diagnosis fluid intake at 3 and 15 months (FFQ and 4‐day 24‐h fluid diaries) ( n = 1275) after diagnosis. Multivariable proportional hazard regression models were used to obtain hazard ratios (HRs) and 95% confidence intervals (CIs) for the association of fluid intake with risk of first and multiple recurrence(s) and progression. Results: During a median overall follow‐up of 4.6 years, 474 patients had one or more recurrence and 142 had progression. A higher first recurrence risk was observed for patients with the highest pre‐diagnosis fluid intakes (≥2300 vs 1500–1900 mL/day: HR 1.38, 95% CI 1.07–1.79), but not for those with the highest post‐diagnosis fluid intakes. HRs were similar for multiple recurrence risk. For progression, each 150 mL/day increase in both pre‐ and post‐diagnosis fluid intake was consistently associated with an increased risk (post‐diagnosis [3 months] FFQ‐based: HR 1.05, 95% CI 1.01–1.09 and diary‐based: HR 1.04, 95% CI 0.99–1.09). Conclusion: High fluid intakes may be associated with higher NMIBC recurrence and especially progression risk. These findings lack a clear explanation but may be related to extensive expansion of the bladder wall or urinary symptoms. Further research is warranted. Meanwhile, these findings do not support recommending high(er) fluid intakes to patients with NMIBC to decrease their recurrence or progression risk.